Skip to content
Review Open access

Phenotypic Presentation of Atypical Familial Partial Lipodystrophy in a Patient With a Rare Mutation in the LMNA Gene: A Case Report and Literature Review

Jan 2026 · Case Reports in Endocrinology · Vol 2026 · 0 citations · 25 references
Medicine

Abstract

Background Variants in the LMNA gene are classically associated with familial partial lipodystrophy type 2 (FPLD2/Dunnigan syndrome). However, certain mutations produce severe multisystemic phenotypes that may mimic congenital generalized lipodystrophy (CGL). This case adds to the literature by delineating the distinct syndromic expression of the LMNA p.Arg349Trp variant and underscoring the need for early recognition to guide cardiovascular and renal surveillance. Clinical Findings A 41‐year‐old woman presented to a specialized diabetes clinic serving low‐income populations with severe lipoatrophy of the face and limbs, relative preservation of truncal adiposity, refractory diabetes, severe hypertriglyceridemia, arterial hypertension, and heart failure. Due to the pattern of lipodystrophy, severe systemic involvement, and absence of compensatory cervicofacial fat accumulation, CGL (Berardinelli–Seip syndrome) was initially suspected. Diagnoses, Interventions and Outcomes Next‐generation sequencing identified a heterozygous pathogenic LMNA variant, c.1045C>T (p.Arg349Trp). At baseline, the patient presented with established proteinuric nephropathy, severe hypertriglyceridemia, and cardiovascular disease. Following multidisciplinary care and an optimized pharmacological protocol, transient improvement in metabolic and glycemic profiles was achieved. However, despite good therapeutic response, socioeconomic barriers disrupted access to high‐cost medications, and she deteriorated to cardiovascular and hepatic failure, dying from cardiogenic shock and sepsis of abdominal origin in less than 2 years of follow‐up. Conclusion This case highlights the high clinical severity of the LMNA p.Arg349Trp variant. Recognizing it as a distinct syndromic entity is crucial to prevent diagnostic delays, enabling timely cardiovascular and renal surveillance, particularly in resource‐limited settings where treatment interruptions can have fatal consequences.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.